Binds Specifically-identified Amino Acid Sequence Patents (Class 530/387.9)
  • Xylanases, Nucleic Acids Encoding Them and Methods for Making and Using Them
    Publication number: 20140298499
    Abstract: The invention relates to enzymes having xylanase, mannanase and/or glucanase activity, e.g., catalyzing hydrolysis of internal ?-1,4-xylosidic linkages or endo-?-1,4-glucanase linkages; and/or degrading a linear polysaccharide beta-1,4-xylan into xylose. Thus, the invention provides methods and processes for breaking down hemicellulose, which is a major component of the cell wall of plants, including methods and processes for hydrolyzing hemicelluloses in any plant or wood or wood product, wood waste, paper pulp, paper product or paper waste or byproduct. In addition, methods of designing new xylanases, mannanases and/or glucanases and methods of use thereof are also provided. The xylanases, mannanases and/or glucanases have increased activity and stability at increased pH and temperature.
    Type: Application
    Filed: December 16, 2013
    Publication date: October 2, 2014
    Applicant: BP Corporation North America Inc.
    Inventors: Kevin A. Gray, Reinhard Dirmeier
  • Methylated Peptides Derived from Tau Protein and Their Antibodies for Diagnosis and Therapy of Alzheimer's Disease
    Publication number: 20140294839
    Abstract: In sporadic Alzheimer's disease, neurofibrillary lesion formation is preceded by extensive post-translational modification of the microtubule associated protein tau. Immunoassays have been developed recently that detect tau in biological specimens, thus providing a means for pre-mortem diagnosis of Alzheimer's disease, which has remained elusive. These assays have been improved by the analysis of relevant post-translational modifications, such as phosphorylation, however opportunity for improvement remains. The present invention addresses this issue by disclosing synthetic methylated peptides derived from the tau protein of paired helical filaments and non-diseased control brain. Alzheimer's disease specificity is provided by the presence or absence of methyl moieties on lysine residues and differences between mono-, di-, and tri-methylation.
    Type: Application
    Filed: October 22, 2012
    Publication date: October 2, 2014
    Inventors: Jeffrey A. Kuret, Kristen E. Funk, Jyanyu Austin Yang, Stefani Thomas
  • RBM3 Protein in Colorectal Cancer Prognostics
    Publication number: 20140295462
    Abstract: The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.
    Type: Application
    Filed: April 9, 2014
    Publication date: October 2, 2014
    Applicant: Atlas Antibodies AB
    Inventors: Mathias Uhlen, Fredrik Ponten, Karin Jirstrom
  • Assays, Methods and Means
    Publication number: 20140294842
    Abstract: A novel class of hydroxylases is described having the amino acid sequence of SEQ ID No. 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the HIF hydroxylase with a substrate. Modulators of HIF hydroxylase are provided for use in the treatment of a condition associated with increased or decreased HIF levels or activity or for the treatment of a condition where it is desirable to modulate HIF levels or activity.
    Type: Application
    Filed: September 16, 2013
    Publication date: October 2, 2014
    Applicant: Isis Innovation Limited
    Inventors: Patrick Henry Maxwell, Christopher William Pugh, Peter John Ratcliffe, Christopher Joseph Schofield
  • PRION PROTEIN ANTIBODIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20140294844
    Abstract: The invention relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of toxicity of A? oligomers. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of Alzheimer's Disease. The invention also relates to methods of medical treatment.
    Type: Application
    Filed: May 9, 2012
    Publication date: October 2, 2014
    Inventors: John Collinge, Andrew J. Nicoll
  • ANTIBODY FOR DETECTING EPITHELIAL OVARIAN CANCER MARKER AND METHOD FOR DIAGNOSING EPITHELIAL OVARIAN CANCER
    Publication number: 20140295455
    Abstract: The present invention provides an antibody capable of specifically recognizing and detecting the highly specific cancer marker with respect to the epithelial ovarian cancer, or a fragment of the antibody. The present invention provides an anti-?1,3-N-acetylglucosaminyltransferase 3 antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase ?1,3-N-acetylglucosaminyltransferase 3 as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.
    Type: Application
    Filed: July 26, 2012
    Publication date: October 2, 2014
    Applicant: National Institute of Advanced Industrial Science and Technology
    Inventors: Maki Sogabe, Tomomi Kubota, Akira Togayachi, Yuzuru Ikehara, Hisashi Narimatsu, Hiromichi Sawaki, Hayao Nakanishi, Toru Nakanishi
  • MITOCHONDRIAL-DERIVED PEPTIDE MOTS3 REGULATES METABOLISM AND CELL SURVIVAL
    Publication number: 20140296139
    Abstract: MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 2, 2014
    Inventors: Pinchas COHEN, Changhan LEE, Laura J. COBB
  • Novel Targets for Regulation of Angiogenesis
    Publication number: 20140294848
    Abstract: The present invention relates to the identification of polynucleotides and polypeptides having increased expression in tumor blood vessels. The invention further relates to the use of the identified polynucleotides and polypeptides, and inhibitors of the polynucleotides and polypeptides, in the regulation of angiogenesis and the diagnosis and treatment of angiogenesis-related diseases such as cancer.
    Type: Application
    Filed: March 24, 2014
    Publication date: October 2, 2014
    Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: NANCY KLAUBER DEMORE, CAM PATTERSON, RAJENDRA BHATI, BRADLEY G. BONE
  • ANTI-NOTCH NRR ANTIBODIES AND METHODS USING SAME
    Publication number: 20140296488
    Abstract: The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: February 11, 2014
    Publication date: October 2, 2014
    Applicant: Genentech, Inc.
    Inventors: Christian W. Siebel, Yan Wu
  • EARLY CHILDHOOD MEMBRANOUS NEPHROPATHY DUE TO CATIONIC BOVINE SERUM ALBUMIN
    Publication number: 20140294850
    Abstract: The invention concerns a biomarker for diagnosing or prognosing childhood Membranous Nephropathy (MN), said biomarker is (i) cationic Bovine Serum Albumin (BSA), and/or (ii) an antibody that binds to a polypeptide of sequence SEQ ID NO: 3. The invention further concerns an antibody or antibody fragment or a composition comprising such an antibody or antibody fragment, wherein said antibody or antibody fragment is specific to an amino acid sequence SEQ ID NO: 3. The invention also concerns a foodstuff likely to contain BSA or cow milk or cow milk extracts, wherein said foodstuff is depleted in BSA.
    Type: Application
    Filed: September 1, 2011
    Publication date: October 2, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicate (INSERM)
    Inventors: Pierre Ronco, Hanna Debiec
  • In Vitro Assessment of Cardiovascular Events by Assay for Neo-Eptitopes of Titin Protein
    Publication number: 20140295469
    Abstract: A bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a titin protein by a proteinase comprises contacting a sample with an antibody specifically binding said neo-epitope and determining the level of binding.
    Type: Application
    Filed: July 6, 2012
    Publication date: October 2, 2014
    Inventors: Diana Julia Leeming, Morten Karsdal, Efstathios Vassiliadis
  • GENE CLUSTER FOR BIOSYNTHESIS OF GRISELIMYCIN AND METHYLGRISELIMYCIN
    Publication number: 20140295457
    Abstract: The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.
    Type: Application
    Filed: October 11, 2012
    Publication date: October 2, 2014
    Inventors: Mark Broenstrup, Claudia Koenig, Luigi Toti, Joachim Wink, Wulf Leuschner, Johann Gassenhuber, Rolf Müller, Silke Wenzel, Tina Binz, Carsten Volz
  • Monoclonal antibodies and diagnostic uses thereof
    Patent number: 8846872
    Abstract: The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: September 30, 2014
    Assignee: MannKind Corporation
    Inventors: Nathalie Kertesz, Sutao Zhu, Chih-Sheng Chiang
  • Anti-HS6ST2 antibodies and uses thereof
    Patent number: 8846870
    Abstract: The present invention provides antibodies that bind to HS6ST2 proteins, pharmaceutical compositions comprising the antibodies as active ingredients, methods for diagnosing cancer using the antibodies, HS6ST2 proteins conjugated to cytotoxic agents and pharmaceutical compositions comprising the HS6ST2 proteins as active ingredients.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: September 30, 2014
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Shigeto Kawai, Naoki Kimura
  • Anti-LRP6 antibodies
    Patent number: 8846041
    Abstract: The invention provides anti-LRP6 antibodies and methods of using the same. A particular aspect of the invention provides for bispecific anti-LRP6 antibodies that inhibit signaling by multiple Wnt isoforms.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: September 30, 2014
    Assignee: Genentech, Inc.
    Inventors: Eric Bourhis, Tim Cao, Rick Carano, Andrea Cochran, Mike Costa, Venita DeAlmeida, James Ernst, Yan Gong, Rami Hannoush, Paul Polakis, Bonnee Rubinfeld, Mark Solloway, Yan Wu
  • In vitro method for diagnosing or predicting hypertension and/or early-stage cardiovascular end-organ damage by determining the concentration of soluble prorenin receptor
    Patent number: 8846324
    Abstract: A method for diagnosis and/or prediction of hypertension and/or cardiovascular end-organ damage is disclosed. The method disclosed comprises the determination of the presence of soluble pro-renin receptor in samples derived from a subject. Furthermore, the use of anti-sPRR antibodies in diagnosis and/or prediction of cardiovascular end-organ damage is encompassed.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: September 30, 2014
    Assignee: CellTrend GmbH
    Inventors: Harald Heidecke, Kai Schulze-Forster
  • Interleukin-31 Monoclonal Antibody
    Publication number: 20140286958
    Abstract: An isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31 is provided. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats.
    Type: Application
    Filed: June 12, 2014
    Publication date: September 25, 2014
    Inventors: Gary F. Bammert, Steven A. Dunham
  • ANTIGEN BINDING PROTEINS
    Publication number: 20140286935
    Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 25, 2014
    Applicant: Glaxosmithkline Intellectual Property Development Limited
    Inventors: Paul HAMBLIN, Alan Lewis, Thomas Matthew Webb
  • ANTIBODIES TO CD1d
    Publication number: 20140286957
    Abstract: Isolated antibodies or antigen binding portions thereof that bind to CD1d. These antibodies and antigen binding portions thereof have application in treatment of conditions involving NKT cell effector function.
    Type: Application
    Filed: April 10, 2014
    Publication date: September 25, 2014
    Applicant: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Jonathan Kannan Nambiar, Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Matthew Pollard, Huseyin Mustafa
  • CHIMERIC HUMAN-LLAMA ANTIGENS AND METHODS OF USE
    Publication number: 20140286976
    Abstract: Provided are chimeric, camelid-human (e.g., llama-human) polypeptides comprising a first antigenic polypeptide portion and a second antigenic polypeptide portion wherein the first antigenic portion is a derived from a first portion of a camelid (e.g., llama) and the second antigenic portion is a human polypeptide homolog of a second portion of the camedid antigen. The chimeric polypeptides are useful inter alia for epitope mapping and generation of antibodies that bind to a desired region of human antigen.
    Type: Application
    Filed: November 5, 2012
    Publication date: September 25, 2014
    Applicant: arGEN-X B.V.
    Inventors: Johannes Joseph Wilhelmus De Haard, Natalie De Jonge, Anna Hultberg, Christophe Blanchetot, Karen Silence, Peter Ulrichts, Torsten Dreier
  • HEPCIDIN, HEPCIDIN ANTAGONISTS AND METHODS OF USE
    Publication number: 20140286953
    Abstract: The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related disorders.
    Type: Application
    Filed: December 11, 2013
    Publication date: September 25, 2014
    Applicant: Amgen Inc.
    Inventors: Barbra Sasu, Mitsuru Haniu, Thomas Charles Boone, Xiao-juan Bi, Grace Ki Jeong Lee, Tara Arvedson, Aaron George Winters, Keegan Cooke, Jackie Z. Sheng
  • Giant Obscurins and Uses Thereof in Cancer Prognosis and Therapy
    Publication number: 20140286932
    Abstract: Provided herein are methods and kits for evaluating potential for invasiveness, metastasis, or recurrence of an epithelial cell cancer. In the methods the expression profile of giant obscurins is detected in a tissue sample of tumor cells or suspected tumor cells and assessed for giant obscuring expression level and distribution therein. Decreased levels or altered distribution of giant obscurins in the cells compared to a control non-invasive standard or to a sample taken at a different point in time is indicative of increased potential of at least one of the invasiveness, metastasis, or recurrence of the epithelial cell cancer. The kit comprises a detection reagent suitable for detecting the presence and distribution of giant obscurins or an amount of the gene product(s) encoding giant obscurins in cells of a tissue sample and instructions for using the detection reagent.
    Type: Application
    Filed: March 21, 2014
    Publication date: September 25, 2014
    Applicants: JOHNS HOPKINS UNIVERSITY, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Aikaterini Kontrogianni-Konstantopoulos, Konstantinos Konstantopoulos, Marey Shriver, Nicole Perry
  • ANTIBODIES BINDING TO AN INTRACELLULAR PRL-1 OR PRL-3 POLYPEPTIDE
    Publication number: 20140286937
    Abstract: We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-I positive patients.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 25, 2014
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Qi Zeng
  • Inhibitors of Metastasis, Methods of Generating Such Inhibitors and Their Therapeutic Applications
    Publication number: 20140286952
    Abstract: The chain of events that explains calcitonin receptor (CTR)-stimulated invasion and metastasis of prostate cancer cells was identified. The CTR-stimulated events depend on the interaction of CTR with the PDZ3 domain of ZO-1. Small peptides and small molecules were identified that inhibit this interaction. The small inhibitory peptides were synthesized and can be used to attenuate or inhibit metastasis in solid cancer tumors.
    Type: Application
    Filed: March 30, 2012
    Publication date: September 25, 2014
    Applicant: Board of Supervisors for the University of Louisia System, acting on behalf of the University of Lou
    Inventor: Girish V. Shah
  • USE OF ANTI-CD83 AGONIST ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES
    Publication number: 20140286950
    Abstract: This invention relates to compositions comprising anti-CD83 agonist antibodies and methods of treating autoimmune disorders (such as inflammatory bowel disease) with anti-CD83 agonist antibodies, as well as articles of manufacture comprising anti-CD83 agonist antibodies.
    Type: Application
    Filed: June 29, 2012
    Publication date: September 25, 2014
    Applicant: Genentech, Inc.
    Inventors: Lauri Diehl, Jennifer Bates, Tao Sai
  • Therapeutic Agents and Uses Thereof
    Publication number: 20140286862
    Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.
    Type: Application
    Filed: October 26, 2012
    Publication date: September 25, 2014
    Inventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
  • Collagen-like Silk Genes
    Publication number: 20140288009
    Abstract: The present invention relates to silk proteins which can be used to produce silk with a collagen-like structure, as well as nucleic acids encoding such proteins. The present invention also relates to recombinant cells and/or organisms which synthesize silk proteins. Silk proteins of the invention can be used for a variety of purposes such as in the production of personal care products, plastics, textiles, and biomedical products.
    Type: Application
    Filed: November 15, 2012
    Publication date: September 25, 2014
    Inventors: Tara D. Sutherland, Victoria Shirley Haritos, Sarah Weisman, John Alan Maurice Ramshaw, Yong Yi Peng, Shoko Okada, Andrew Allan Walker
  • CHARACTERIZATION OF CHO-MIF GENE AND PROTEIN, AND USE THEREOF
    Publication number: 20140287443
    Abstract: The present invention is concerned with the specific and highly sensitive detection of specific CHO-MIF (macrophage migration inhibitory factor from Chinese Ovarian Hamster cell line) complexes in the production of anti-MIF antibodies. The present invention is further concerned with the provision of specific antibodies which can be used for a CHO-MIF detection method. The present invention is also concerned with a CHO MIF knockout cell line and use thereof. The present invention also provides preparations obtained from recombinant production in CHO cell lines which are essentially free of CHO-MIF.
    Type: Application
    Filed: October 4, 2012
    Publication date: September 25, 2014
    Inventors: Randolf J. Kerschbaumer, Dirk Voelkel, Gerhard Antoine, Friedrich Scheiflinger, Geert C. Mudde
  • MET-BINDING AGENTS AND USES THEREOF
    Publication number: 20140286951
    Abstract: The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Inventors: Austin L. GURNEY, Ming-Hong Xie, Christopher John Bond
  • ANTIBODY SPECIFIC TO PROFILAGGRIN C-TERMINAL DOMAIN, AND USE THEREOF
    Publication number: 20140287431
    Abstract: The present invention provides an antibody specific to a C-terminal domain of a human profilaggrin gene, wherein the C-terminal domain is a peptide comprising the amino acid sequence set forth in SEQ ID NO:1 or a variant thereof, a method for detecting a filaggrin gene mutation using the antibody, and a kit for the detection.
    Type: Application
    Filed: November 8, 2012
    Publication date: September 25, 2014
    Inventors: Toshihiko Hibino, Mami Yamamoto, Masaya Takagi, Junichi Sakabe, Yoshiki Tokura
  • TAU PROTEASE COMPOSITIONS AND METHODS OF USE
    Publication number: 20140286954
    Abstract: Disclosed are mammalian tau proteases, as well as proteolytically-active fragments, variants, and mutants thereof. Also disclosed are polynucleotides and recombinant expression vectors that encode these polypeptides, as well as methods for producing such proteins in selected recombinant host cells, and for using the compositions in a variety of diagnostic and analytical assays.
    Type: Application
    Filed: May 18, 2012
    Publication date: September 25, 2014
    Applicant: Oligomerix, Inc
    Inventors: James G. Moe, Eliot Davidowitz, Patricia Lopez
  • NUCLEIC ACID CONSTRUCT COMPRISING NUCLEIC ACID DERIVED FROM GENOME OF HEPATITIS C VIRUS OF GENOTYPE 3a
    Publication number: 20140286995
    Abstract: A nucleic acid includes, in the following order, a 5? untranslated region comprising a particular nucleotide sequence of the genome of hepatitis C virus genotype 3a; a nucleotide sequence encoding a particular amino acid sequence of an NS3 protein, a nucleotide sequence encoding a particular amino acid sequence of an NS4A protein, a nucleotide sequence encoding a particular amino acid sequence of an NS4B protein, a nucleotide sequence encoding a particular amino acid sequence of an NS5A protein, a nucleotide sequence encoding a particular amino acid sequence of an NS5B protein of the hepatitis C virus genotype 3a; and a 3? untranslated region comprising a particular nucleotide sequence of a genome of hepatitis C virus genotype 3a.
    Type: Application
    Filed: August 31, 2012
    Publication date: September 25, 2014
    Applicants: Japan as Represented by Director-General of National Institute of Infectious Diseases, Toray Industries, Inc., INSERM Institutut National de la Sante et de la Recherche Medicale
    Inventors: Takaji Wakita, Mohsan Saeed, Patrick Maurel, Claire Gondeau, Hiroshi Yokokawa
  • COMPOSITIONS AND METHODS FOR MODULATING RSV INFECTION AND IMMUNITY
    Publication number: 20140288267
    Abstract: Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.
    Type: Application
    Filed: April 15, 2014
    Publication date: September 25, 2014
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Service
    Inventors: Ralph A. Tripp, Les Jones, Larry J. Anderson
  • Synthetic peptide constructs for the diagnosis and treatment of periodontis associated with
    Patent number: 8841420
    Abstract: The present invention relates to an oral composition and an immunogenic composition for the suppression of the pathogenic effects of the intra-oral bacterium Porphyromonas gingivalis associated with periodontal disease.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: September 23, 2014
    Assignee: The University of Melbourne
    Inventors: Eric Charles Reynolds, Neil Martin O'Brien-Simpson, Nada Slakeski
  • Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II
    Patent number: 8841423
    Abstract: Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: September 23, 2014
    Assignee: University of Iowa Research Foundation
    Inventors: Mark E. Anderson, Peter J. Mohler, Douglas R. Spitz, Jr., Jeffrey Robert Erickson
  • Novel Anti-Human IL-23 Receptor Antibody
    Publication number: 20140275490
    Abstract: [Problem] An object of the present invention is to provide an anti-human IL-23R antibody having excellent activity and/or cross-reactivity compared to conventional IL-23R antibodies, and means for using the antibody to prevent or treat various diseases in which human IL-23R is involved in pathogenesis. [Means for Solution] An anti-human IL-23R antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:5, 9, 13, 17, 21, 25 or 29 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:7, 11, 15, 19, 23, 27 or 31.
    Type: Application
    Filed: March 30, 2012
    Publication date: September 18, 2014
    Applicant: Astellas Pharma Inc.
    Inventors: Makoto Ohori, Takanori Sasaki, Hiromu Sato, Katsunari Taguchi
  • INTERNALIZING HUMAN MONOCLONAL ANTIBODIES TARGETING PROSTATE AND OTHER CANCER CELLS
    Publication number: 20140271685
    Abstract: In various embodiments various cancer specific antibodies and immunoconjugates are provided. In certain embodiments the antibodies specifically bind and are internalized into a prostate cancer cell, where the antibodies specifically binds cells that express or overexpress a CD46, and where the antibodies specifically bind sushi domain 1 of said CD46 (CD46 CPP1).
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Inventor: BIN LIU
  • HCV CORE LIPID BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20140272931
    Abstract: The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.
    Type: Application
    Filed: December 23, 2013
    Publication date: September 18, 2014
    Applicant: Abbott Laboratories
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • BRI2 AS A NOVEL BIOMARKER FOR ALZHEIMER'S DISEASE
    Publication number: 20140271463
    Abstract: The disclosure relates to the use of altered BRI2 levels as a biomarker for the risk of developing Alzheimer's disease. Novel treatments based on altered BRI2 levels and anti-BRI2 antibodies are also provided.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Stichting VU-VUmc
    Inventors: Marta DEL CAMPO MILAN, Cornelia Ramona Jimenez, Chrlott Elisabeth Teunissen
  • FELINE BITTER TASTE RECEPTORS AND METHODS
    Publication number: 20140273001
    Abstract: A family of novel feline bitter taste receptors, referred to as feline TAS2R (fTAS2R), are disclosed herein. Isolated polynucleotides encoding the novel feline bitter taste receptors and chimeric polypeptides are also disclosed, as are expression vectors and host cells for expression of the novel feline bitter taste receptors. Methods of identifying compounds that bind to the novel feline bitter taste receptors and modulate their activity are disclosed.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 18, 2014
    Applicant: AFB International
    Inventors: Michelle M. Sandau, Nancy E. Rawson
  • USE OF MYCOBACTERIUM AVIUM PARATUBERCULOSIS PEPTIDES TO DIAGNOSE TYPE 1 DIABETES
    Publication number: 20140271701
    Abstract: The present invention concerns antibodies recognizing Mycobacterium avium paratuberculosis epitopes able to cross-reacting with the beta-cell antigen ZnT8 to be used as early biomarkers of type 1 diabetes, epitopes for in vitro prognostic and diagnostic methods suitable to reveal a risk to develop type 1 diabetes, therapies for the prevention of T1D by avoiding, controlling or monitoring Mycobacterium paratuberculosis infection.
    Type: Application
    Filed: October 25, 2012
    Publication date: September 18, 2014
    Inventors: Leonardo Antonio Sechi, Roberto Mallone
  • NOVEL RETROELEMENT FOUND IN MOLLUSKS
    Publication number: 20140272974
    Abstract: This invention relates to a novel retroelement, named “Steamer”, found in mollusks, more specifically Mya arenaria, that is associated with haemic neoplasia in these organisms. Haemic neoplasia (HN) is a recognizable leukemic-like disease. The invention provides the retroelement protein, antibodies to the protein, nucleic acids encoding the protein, probes, primer, gene constructs comprising the nucleic acids, host cells comprising the nucleic acids, and methods of using.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Stephen P. Goff, W. Ian Lipkin, Gloria Arriagada, Carol Reinisch, James Sherry, Charles Walker
  • CD20 CONFORMATIONAL ISOMERS AND METHODS OF USING
    Publication number: 20140271619
    Abstract: Described herein are methods of screening for compounds that bind to conformational isomers of CD20 polypeptides. Also described are antibodies that bind to conformational isomers of CD20 polypeptides.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 18, 2014
    Inventor: Ross Stewart Chambers
  • ANTIBODIES TO HGF AND COMPOSITIONS CONTAINING
    Publication number: 20140271459
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for HGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-HGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-HGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-HGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with HGF.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: ALDERBIO HOLDINGS LLC
    Inventors: Benjamin H. Dutzar, Katie Anderson, Brian R. Kovacevich, Andrew L. Feldhaus, John A. Latham, Leon F. Garcia-Martinez
  • COMPOSITIONS AND METHODS FOR TREATING CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASES
    Publication number: 20140271700
    Abstract: Described herein are isolated polypeptides each containing one or more receptor-binding sites of toxin A (tcdA) of Clostridium difficile (Cd), nucleic acids encoding the polypeptides, and methods of using the polypeptides and nucleic acids.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: National Health Research Institutes
    Inventors: Pele Choi-Sing Chong, Jui-Hsin Huang, Chih-Hsiang Leng
  • ANTIBODIES THAT BIND INTEGRIN ALPHA-V BETA-8
    Publication number: 20140271478
    Abstract: Provided herein are antibodies with high affinity for the ?8 subunit of ??8.
    Type: Application
    Filed: August 17, 2012
    Publication date: September 18, 2014
    Applicant: The Regents of the University of California
    Inventors: Stephen Nishimura, Jianlong Lou, Jody Lynn Baron, James Marks
  • Anti-GP73 monoclonal antibodies and methods of obtaining the same
    Publication number: 20140271651
    Abstract: Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Inventors: Bailin Tu, Robert N. Ziemann, Bryan C. Tieman, Philip M. Hemken
  • NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USES THEREOF
    Publication number: 20140271655
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.
    Type: Application
    Filed: July 18, 2011
    Publication date: September 18, 2014
    Inventor: Antonio Lanzavecchia
  • ANTIBODIES RECOGNIZING HUMAN TIMP1 PROTEIN
    Publication number: 20140275491
    Abstract: The present invention is directed to anti-human antibodies recognizing human TIMP1 and the method for making the same. Specifically, the anti-human antibodies are produced using chicken IgY antibodies. The antibodies described herein can be used for the detection and quantification of human TIMP1 protein in patient samples, including bodily fluids, or tissue samples.
    Type: Application
    Filed: March 15, 2014
    Publication date: September 18, 2014
    Applicant: Corgenix Medical Corporation
    Inventors: Kelly R. Pitts, Joseph A. Chapo
  • Methods for Detecting Ehrlichia Infection
    Publication number: 20140273026
    Abstract: The present invention provides an isolated and purified heat shock protein 60 (Hsp60) peptide having the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to a vaccine against Ehrlichia comprising a peptide homologous to the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to an antibody directed against a peptide homologous to the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to a method of determining whether a subject is infected with Ehrlichia, comprising the steps of: contacting a sample from a subject with the antibody described herein; and detecting a resulting antibody reaction, wherein a positive reaction indicates the subject is infected with Ehrlichia.
    Type: Application
    Filed: February 6, 2014
    Publication date: September 18, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: David H. Walker, Sunil Thomas